

Continuous Postoperative Pericardial Flush; to evaluate the effects of pericardial flush with a crystalloid on blood loss after CABG.

Gepubliceerd: 14-06-2015 Laatste bijgewerkt: 15-05-2024

Continuous postoperative pericardial flush (CPPF) with a crystalloid is likely to enhance the evacuation of activated and contaminated pericardial blood and clots out of the pericardial cavity and may contribute to a reduction of (excessive) blood...

Ethische beoordeling	Niet van toepassing
Status	Werving gestart
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON24893

Bron

NTR

Verkorte titel

CPPF

Aandoening

Postoperative blood loss, Cardiac tamponade, Transfusion requirements, Health-related quality of life, Cost-effectiveness.

Ondersteuning

Primaire sponsor: Academic Medical Center (AMC), Amsterdam, The Netherlands

Overige ondersteuning: ZonMw DoelmatigheidsOnderzoek Type I Program

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

- 1: Mediastinal chest tube drainage (MCTD) at 12 hours postoperatively.

- 2: The difference in haemoglobin levels between the start of CPPF and 12 hours postoperative (ΔHb).

Toelichting onderzoek

Doel van het onderzoek

Continuous postoperative pericardial flush (CPPF) with a crystalloid is likely to enhance the evacuation of activated and contaminated pericardial blood and cloths out of the pericardial cavity and may contribute to a reduction of (excessive) blood loss and here related transfusion requirements and need for re-operation for bleeding after CABG. Flushing the pericardial cavity is likely to reduce the amount of cloths and old blood remains after removal of the chest tubes and consequently, the incidence of early and late cardiac effusions and tamponade may be reduced.

Onderzoeksopzet

T-1 = Randomization. T0 = Arrival on ICU. T12 = 12 hours postoperatively. T24 = 24 hours postoperatively. TD = Discharge from hospital. T6m = Follow-up 6 months postoperatively.

Onderzoeksproduct en/of interventie

CPPF will be performed continuously after operation (using a flushing system with a set flow rate of 500ml/hour), starting from the moment the sternum is closed until the total flushing volume of 7000ml has been completely infused.

Contactpersonen

Publiek

Academic Medical Center at the University of Amsterdam

Johan S.J. Manshanden
Meibergdreef 9

Amsterdam 1105 AZ
The Netherlands
T +31 (0) 20 - 566 81 88

Wetenschappelijk

Academic Medical Center at the University of Amsterdam

Johan S.J. Manshanden
Meibergdreef 9

Amsterdam 1105 AZ
The Netherlands
T +31 (0) 20 - 566 81 88

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

All adult patients (>18y) undergoing surgery for CABG.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

Patients are not eligible for this study if the following criteria apply:

- Previous CABG;
- Emergency surgery;
- Preoperative use of Dabigatran, Rivaroxaban, Apixaban, Clopidogrel, Brilique or Prasugrel;
- <18 years and/or inability to understand study information / give informed consent;
- Participation in any study involving an investigational drug or device;

Onderzoekopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Parallel
Toewijzing:	Gerandomiseerd
Blinding:	Enkelblind
Controle:	Placebo

Deelname

Nederland	
Status:	Werving gestart
(Verwachte) startdatum:	01-01-2014
Aantal proefpersonen:	170
Type:	Verwachte startdatum

Ethische beoordeling

Niet van toepassing	
Soort:	Niet van toepassing

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 44986
Bron: ToetsingOnline
Titel:

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL5069
NTR-old	NTR5200

Register

CCMO

OMON

ID

NL43190.018.13

NL-OMON44986

Resultaten